Scorpius Holdings' Q1 Revenue Plunges 94%, Going Concern Doubts Mount

TL;DR

**SCPX is circling the drain with a 94% revenue drop and a 'going concern' warning; avoid at all costs.**

AI Summary

Scorpius Holdings, Inc. (SCPX) reported a significant decline in revenue and a substantial increase in net loss for the three months ended March 31, 2025. Revenue plummeted to $212,264 from $3,513,948 in the prior-year period, representing a 94% decrease. The net loss attributable to Scorpius Holdings, Inc. widened to $10,714,555, compared to a net loss of $4,417,549 for the three months ended March 31, 2024. Key business changes include a $5,733,298 loss on lease assignment and termination and a $721,564 loss on disposal of long-lived assets, indicating a significant restructuring of its manufacturing operations. The company also recognized a $780,000 loss on settlement of a related party receivable with Elusys Holdings, controlled by CEO Jeffrey Wolf. SCPX faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $297.9 million and only $188,914 in cash and cash equivalents as of March 31, 2025. Strategic outlook involves exploring additional equity and debt financings, equipment sale leasebacks, and partnerships to fund operations, particularly the biomanufacturing facility in San Antonio.

Why It Matters

This filing reveals a company in deep financial distress, with revenue nearly wiped out and a net loss more than doubling year-over-year. For investors, the 'going concern' warning is a critical red flag, indicating a high risk of bankruptcy or significant dilution. Employees face job insecurity as the company struggles to fund operations and mitigate impacts from manufacturing lease terminations. Customers may experience disruptions in service offerings due to the company's financial instability and reliance on third-party suppliers. In the competitive CDMO market, SCPX's struggles could allow larger, more stable players to consolidate market share, further pressuring Scorpius's viability.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt about the Company's ability to continue as a going concern" due to an accumulated deficit of $297.9 million, a net loss of $11.3 million for the quarter, and only $0.2 million in cash as of March 31, 2025. Furthermore, SCPX is in default on its 2025 Non-Convertible Promissory Notes, Related Party, for failing to repay amounts due and failing to pay indebtedness in excess of $150,000 to certain third parties.

Analyst Insight

Investors should immediately divest any holdings in SCPX due to the severe financial distress, explicit going concern warning, and significant operational losses. The company's inability to generate substantial revenue and its default on debt obligations indicate an extremely high risk of further value erosion or bankruptcy. Do not attempt to 'buy the dip' as there is no clear path to recovery.

Financial Highlights

debt To Equity

N/A

revenue

$212,264

operating Margin

N/A

total Assets

$23,585,574

total Debt

$30,148,342

net Income

$(10,714,555)

eps

$(1.16)

gross Margin

N/A

cash Position

$188,914

revenue Growth

-94.0%

Revenue Breakdown

Key Numbers

• $212,264 — Revenue (94% decrease from $3,513,948 in Q1 2024, indicating severe operational decline.)
• $(10,714,555) — Net Loss Attributable to SCPX (More than doubled from $(4,417,549) in Q1 2024, highlighting worsening profitability.)
• $(297,893,225) — Accumulated Deficit (Significant and growing deficit as of March 31, 2025, indicating historical unprofitability.)
• $188,914 — Cash and Cash Equivalents (Critically low cash balance as of March 31, 2025, down from $1,027,997 at December 31, 2024.)
• $5,733,298 — Loss on Lease Assignment and Termination (Major one-time expense in Q1 2025, reflecting significant operational restructuring.)
• $780,000 — Loss on Settlement of Related Party Receivable (Expense from settling a receivable with Elusys Holdings, controlled by the CEO.)
• 61,142,712 — Shares Outstanding (As of August 22, 2025, indicating potential for further dilution given financing needs.)
• $(1.16) — Net Loss Per Common Share (For Q1 2025, compared to $(31.38) in Q1 2024 (adjusted for reverse stock split), showing continued per-share losses.)

Key Players & Entities

• Scorpius Holdings, Inc. (company) — registrant of the 10-Q filing
• Jeffrey Wolf (person) — Chairman, Chief Executive Officer, and President of Scorpius Holdings, Inc., also controls Elusys Holdings, Inc.
• Elusys Holdings, Inc. (company) — company controlled by Jeffrey Wolf, involved in a related party receivable settlement
• SEC (regulator) — Securities and Exchange Commission
• $212,264 (dollar_amount) — revenue for the three months ended March 31, 2025
• $3,513,948 (dollar_amount) — revenue for the three months ended March 31, 2024
• $10,714,555 (dollar_amount) — net loss attributable to Scorpius Holdings, Inc. for the three months ended March 31, 2025
• $297.9 million (dollar_amount) — accumulated deficit as of March 31, 2025
• $188,914 (dollar_amount) — cash and cash equivalents as of March 31, 2025
• $780,000 (dollar_amount) — loss on settlement of related party receivable for the three months ended March 31, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has substantial doubt about its ability to continue as a going concern due to a critically low cash balance of $188,914 as of March 31, 2025, and an accumulated deficit of $297.9 million. This necessitates aggressive financing strategies.
• Severe Revenue Decline [high — operational]: Revenue decreased by 94% to $212,264 in Q1 2025 from $3,513,948 in Q1 2024. This indicates a severe contraction in business operations.
• Significant Restructuring Costs [high — operational]: The company incurred substantial one-time expenses, including a $5,733,298 loss on lease assignment and termination and a $721,564 loss on disposal of long-lived assets, reflecting major changes in its manufacturing operations.
• Related Party Transaction Risk [medium — financial]: A $780,000 loss was recognized on the settlement of a related party receivable with Elusys Holdings, controlled by CEO Jeffrey Wolf. Such transactions can present conflicts of interest and opacity.
• High Leverage and Lease Obligations [medium — financial]: Despite reductions, significant finance lease liabilities remain at $10,283,722 (gross) and operating lease liabilities at $664,361 (net). These obligations, along with convertible and non-convertible notes, contribute to a high debt burden.
• Dilution Risk from Financing [high — financial]: With 61,142,712 shares outstanding and a critical need for additional equity and debt financing, existing shareholders face a high risk of significant dilution.

Industry Context

The biomanufacturing sector is capital-intensive and subject to stringent regulatory oversight. Companies often face long development cycles and significant R&D costs. The current environment may see increased consolidation and a focus on operational efficiency due to economic pressures.

Regulatory Implications

SCPX's financial distress and going concern issues could attract scrutiny from regulatory bodies like the SEC, particularly concerning disclosures and potential future financings. Compliance with manufacturing regulations (e.g., FDA's cGMP) remains critical for any operational continuity.

What Investors Should Do

1. Monitor financing activities closely.
2. Evaluate the impact of restructuring on future operations.
3. Assess management's ability to execute turnaround strategy.
4. Consider the high risk of further dilution.

Key Dates

• 2025-03-31: End of First Quarter 2025 — Reporting period showing a 94% revenue decline and a significant increase in net loss, highlighting severe operational challenges and substantial restructuring costs.
• 2025-03-31: Cash and Cash Equivalents Balance — Stood at $188,914, a critical low that raises substantial doubt about the company's ability to continue as a going concern.
• 2025-03-31: Accumulated Deficit — Reached $(297,893,225), underscoring a history of unprofitability and a significant financial hole.
• 2025-03-31: Loss on Lease Assignment and Termination — Recorded as $5,733,298, indicating major operational restructuring and a significant one-time expense.
• 2025-03-31: Loss on Disposal of Long-Lived Assets — Recorded as $721,564, further evidence of operational restructuring and asset divestitures.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by net income or additional paid-in capital. (Indicates the company's long-term unprofitability, with a deficit of $297.9 million as of March 31, 2025.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Substantial doubt exists for SCPX due to its low cash and significant losses, impacting investor confidence and potential financing.)

Lease Assignment and Termination

The process of transferring lease obligations to another party or ending a lease agreement prematurely, often incurring costs. (SCPX incurred a significant loss of $5,733,298 from these activities, signaling major operational changes.)

Related Party Receivable

An amount owed to a company by an individual or entity that has a close relationship with the company, such as an executive or a subsidiary. (A $780,000 loss was recognized on settling such a receivable with Elusys Holdings, controlled by the CEO.)

Loss on Disposal of Long-Lived Assets

The financial loss incurred when an asset (like property or equipment) is sold or disposed of for less than its book value. (SCPX reported a $721,564 loss, indicating the sale or write-off of operational assets.)

Year-Over-Year Comparison

Compared to the prior year's first quarter, Scorpius Holdings, Inc. has experienced a dramatic downturn. Revenue has plummeted by 94%, from $3,513,948 to $212,264. The net loss attributable to SCPX has more than doubled, widening from $4,417,549 to $10,714,555. This period also saw significant one-time charges related to operational restructuring, including lease terminations and asset disposals, which exacerbated the already dire financial performance and contributed to a worsening going concern assessment.

Key Financial Figures

• $0.0002 — were 61,142,712 shares of Common Stock, $0.0002 par value per share, outstanding. Tabl

Filing Documents

• scpx-20250331x10q.htm (10-Q) — 1578KB
• scpx-20250331xex31d1.htm (EX-31.1) — 28KB
• scpx-20250331xex31d2.htm (EX-31.2) — 27KB
• scpx-20250331xex32d1.htm (EX-32.1) — 12KB
• scpx-20250331xex32d2.htm (EX-32.2) — 13KB
• 0001558370-25-011734.txt ( ) — 7944KB
• scpx-20250331.xsd (EX-101.SCH) — 63KB
• scpx-20250331_cal.xml (EX-101.CAL) — 81KB
• scpx-20250331_def.xml (EX-101.DEF) — 212KB
• scpx-20250331_lab.xml (EX-101.LAB) — 548KB
• scpx-20250331_pre.xml (EX-101.PRE) — 367KB
• scpx-20250331x10q_htm.xml (XML) — 1456KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024 2 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the three months ended March 31, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) for the three months ended March 31, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2025 and 2024 6 Notes to the Condensed Consolidated Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 35

SIGNATURES

SIGNATURES 38 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and our actual results could differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, our ability to raise additional capital to support our manufacturing operations and other operations, our ability to develop products of commercial value and to identify the outcome of research and development activities, our reliance on third-parties, our ability to successfully operate a manufacturing facility, competitive developments, the effect of current and future legislation and regulation and regulatory actions, as well as other risks described more fully in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission (the "SEC"). Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict,

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS SCORPIUS HOLDINGS, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2025 2024 (unaudited) Current Assets Cash and cash equivalents $ 188,914 $ 1,027,997 Short-term investments 60,248 135,143 Accounts receivable 209,776 143,469 Prepaid expenses and other current assets 1,377,477 1,755,658 Inventory - raw materials 203,663 198,688 Total Current Assets 2,040,078 3,260,955 Long Term Assets Property and equipment, net 10,500,587 12,315,460 Operating lease right-of-use asset 664,361 4,803,361 Finance lease right-of-use asset 10,283,722 17,223,359 Other assets — 203,135 Deposits 96,826 271,449 Related party receivable — 1,100,000 Total Assets $ 23,585,574 $ 39,177,719 Liabilities and Stockholders' (Deficit) Equity Current Liabilities Accounts payable $ 4,474,312 $ 3,227,313 Deferred revenue 1,474,949 1,466,094 Operating lease liability, current portion 166,688 474,972 Finance lease liability, current portion 907,741 945,058 Accrued expenses and other liabilities 2,683,375 2,160,258 Convertible promissory notes payable, related party 12,043,000 16,015,400 Non-convertible promissory notes payable, related party 1,390,000 — Total Current Liabilities 23,140,065 24,289,095 Long Term Liabilities Operating lease liability, net of current portion 652,006 3,036,157 Finance lease liability, net of current portion 5,588,271 8,076,989 Warrants 768,000 2,098,000 Total Liabilities 30,148,342 37,500,241 Commitments and Contingencies (Notes 7, 12, and 13) Stockholders' (Deficit) Equity Common stock, $ 0.0002 par value; 250,000,000 shares authorized, 12,387,712 and 5,083,268 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 2,478 1,017 Additional paid-in capital 296,310,690 293,253,163 Accumulated deficit ( 297,893,225 ) ( 287,178,670 ) Acc

View Full Filing

View this 10-Q filing on SEC EDGAR